# Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

> **NCT00689000** · PHASE1,PHASE2 · COMPLETED · sponsor: **Chroma Therapeutics** · enrollment: 57 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Multiple Myeloma

## Interventions

- **DRUG:** CHR-2797 (tosedostat): Aminopeptidase inhibitor

## Key facts

- **NCT ID:** NCT00689000
- **Lead sponsor:** Chroma Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2010-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00689000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00689000, "Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00689000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*